NASDAQ$TLPH
AcelRx Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Talphera announced first quarter 2024 financial results and provided a corporate update.
Talphera reported a net loss from continuing operations of $4.0 million for the first quarter of 2024, compared to net income of $0.1 million for the same period in 2023. As of March 31, 2024, the company's cash and cash equivalents balance was $18.6 million.
- First patients at multiple sites are expected to be enrolled in the NEPHRO CRRT registrational study in Q2 2024.
- Dr. Shakil Aslam, an expert in renal diseases, including acute kidney injury, joined Talphera as Chief Development Officer.
- Cash and investments at March 31, 2024 were $18.6 million.
- Combined R&D and SG&A expenses for the first quarter of 2024 totaled $4.2 million.
Headline financials
Revenue & EPS history
AcelRx · Revenue · Quarterly
$0
Forward guidance
Talphera expects the NEPHRO study will complete quickly once patients begin enrolling and plans to provide an updated expected study completion date. Talphera anticipates Dr. Aslam's nephrology expertise will support the development and commercial preparation of Niyad.
Tailwinds
- First patients expected to be enrolled in the NEPHRO CRRT registrational study in Q2 2024.
- Clinical trial agreements with five large academic institutions have been finalized.
- Dr. Shakil Aslam joined Talphera as Chief Development Officer.
- Talphera expects the NEPHRO study will complete quickly once patients begin enrolling.
- Dr. Aslam's nephrology expertise will support the development and commercial preparation of Niyad.
Headwinds
- Initial site activation for the NEPHRO study has taken longer than expected.
- Previous guidance of having top-line data available by September 30 will be revised.
- Net loss from continuing operations of $4.0 million.
- The company anticipates a revision to the expected completion date for the NEPHRO study.
- Delays in site activation have impacted the timeline for top-line data availability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-2.7%
Avg return
Earnings day
-3.4%
Avg return
5 days after
+1.1%
Avg return
30 days after
32%
20 / 62 earnings
Positive
+23.5%
Q4 2017
Best reaction
-46.9%
Q4 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.7% | -7.0% | — | |
| Q3 2025 | -18.6% | +3.9% | -7.8% | |
| Q2 2025 | +0.0% | +14.0% | +118.6% | |
| Q1 2025 | -3.9% | +2.0% | -3.9% | |
| Q4 2024 | +6.0% | +2.0% | +2.0% | |
| Q3 2024 | -2.2% | -25.3% | -28.6% | |
| Q2 2024 | -5.5% | +2.2% | -1.1% | |
| Q1 2024 | -1.0% | +4.9% | -4.9% | |
| Q4 2025 | +0.0% | -1.9% | +1.9% | |
| Q4 2023 | +1.6% | -12.0% | -4.0% | |
| Q3 2023 | -9.7% | -11.5% | +40.4% | |
| Q2 2023 | -7.4% | -18.9% | -8.4% | |
| Q1 2023 | +14.5% | +14.5% | +79.7% | |
| Q4 2022 | -8.3% | -16.7% | -6.9% | |
| Q3 2022 | +22.3% | +16.0% | +22.3% | |
| Q2 2022 | +12.5% | +33.3% | +16.7% | |
| Q1 2022 | +4.8% | +23.8% | -4.8% | |
| Q4 2021 | -22.7% | -29.5% | -38.6% | |
| Q3 2021 | -10.1% | -8.9% | -34.2% | |
| Q2 2021 | -20.5% | -10.3% | -12.8% | |
| Q1 2021 | +11.2% | +9.6% | +18.3% | |
| Q4 2020 | -16.2% | -21.6% | -97.0% | |
| Q3 2020 | -20.8% | -21.3% | -16.9% | |
| Q2 2020 | -7.6% | -0.8% | -12.9% | |
| Q1 2020 | -1.3% | -9.7% | -11.0% | |
| Q4 2019 | -7.8% | -18.4% | +25.2% | |
| Q3 2019 | -1.5% | -12.3% | -7.9% | |
| Q2 2019 | -5.8% | -7.4% | -4.1% | |
| Q1 2019 | -10.7% | -10.1% | -34.8% | |
| Q4 2018 | -9.4% | -14.4% | -4.4% | |
| Q3 2018 | +2.9% | -14.5% | -18.8% | |
| Q2 2018 | +5.7% | +7.5% | +17.0% | |
| Q1 2018 | +0.0% | +2.0% | +48.0% | |
| Q4 2017 | +23.5% | +26.5% | +29.4% | |
| Q3 2017 | +1.5% | -5.1% | +7.7% | |
| Q2 2017 | -24.4% | -25.6% | -15.4% | |
| Q1 2017 | -3.7% | -7.4% | -16.7% | |
| Q4 2016 | +11.5% | +3.3% | +3.3% | |
| Q3 2016 | -3.6% | -7.1% | +1.8% | |
| Q2 2016 | +19.8% | +17.8% | +5.9% | |
| Q1 2016 | -6.2% | — | — | |
| Q4 2015 | -8.7% | — | — | |
| Q3 2015 | +13.5% | — | — | |
| Q2 2015 | +8.0% | — | — | |
| Q1 2015 | -24.6% | — | — | |
| Q4 2014 | -46.9% | — | — | |
| Q3 2014 | +14.7% | — | — | |
| Q2 2014 | -5.1% | — | — | |
| Q1 2014 | -5.6% | — | — | |
| Q4 2013 | +7.0% | — | — | |
| Q3 2013 | -0.4% | — | — | |
| Q2 2013 | -12.9% | — | — | |
| Q1 2013 | -3.6% | — | — | |
| Q4 2012 | -5.0% | — | — | |
| Q3 2012 | -5.8% | — | — | |
| Q2 2012 | -2.3% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -5.9% | — | — | |
| Q3 2011 | -0.7% | — | — | |
| Q2 2011 | +2.8% | — | — | |
| Q1 2011 | +5.1% | — | — | |
| Q4 2010 | -3.1% | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro